StreetInsider.com News Articles

Marvel Biosciences Granted Chinese Patent for Lead Therapeutic Candidate MB-204

Mon, 18 Aug 2025 17:05:00 -0400

Calgary, Alberta--(Newsfile Corp. - August 18, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, today announced that the China National Intellectual Property Administration (CNIPA) has granted patent number ZL202180020893.4, titled "Purine Compounds for Treating Disorders". The patent covers the composition of matter for Marvel's lead asset, MB-204.

MB-204 is a novel, fluorinated derivative of the adenosine A2A receptor antagonist Istradefylline, engineered for superior potency, longer duration, and improved tolerability. It has demonstrated

Marvel Biosciences Granted Chinese Patent for Lead Therapeutic Candidate MB-204

Mon, 18 Aug 2025 17:05:00 -0400

MB-204 is a novel, fluorinated derivative of the adenosine A2A receptor antagonist Istradefylline, engineered for superior potency, longer duration, and improved tolerability. It has demonstrated

Marvel Announces the Second of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide Following Cessation of Drug Treatment

Wed, 30 Apr 2025 07:00:00 -0400

Calgary, Alberta--(Newsfile Corp. - April 30, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to share part of the second final data set from its preclinical Rett syndrome study conducted in collaboration with Dr. Julie Le Merrer and Dr. Jerome Becker at the iBraiN Institute.

The study evaluated MB-204, Marvel's lead compound (10 mg/kg oral once daily), in comparison to Trofinetide (100 mg/kg injected i.p. once daily), the only FDA and Health Canada approved treatment for Rett syndrome. Mecp2 mice were treated for approximately two

Marvel Announces the Second of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide Following Cessation of Drug Treatment

Wed, 30 Apr 2025 07:00:00 -0400

Marvel Biosciences to Give Oral Presentation at The Annual IRSF Rett Syndrome Scientific Meeting

Wed, 16 Apr 2025 07:00:00 -0400

Calgary, Alberta--(Newsfile Corp. - April 16, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (together "Marvel"), are pleased to announce their acceptance to give an oral presention at the International Rett Syndrome Foundation (IRSF) Scientific Meeting, taking place June 9-11^th, 2025.

Dr. Mark Williams, Chief Science Officer of Marvel, will present on behalf of the Company and its research collaborators, Dr. Julie Le Merrer and Dr. Jérôme Becker from the iBraiN Institute in Tours, France. The presentation will highlight Marvel's most recent preclinical studies of MB-204 in Rett Syndrome and Autism Spectrum

Marvel Biosciences to Give Oral Presentation at The Annual IRSF Rett Syndrome Scientific Meeting

Wed, 16 Apr 2025 07:00:00 -0400

Marvel Biosciences Selected to Present Alzheimer's Research at the 2025 Alzheimer's Association International Conference

Mon, 14 Apr 2025 07:00:00 -0400

Calgary, Alberta--(Newsfile Corp. - April 14, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), is pleased to announce that it has been invited to present its latest research findings at the Alzheimer's Association International Conference (AAIC), taking place in July 2025.

The Company will present preclinical data from its acute Alzheimer's disease study, conducted in collaboration with Professor Emmanuel Planel, a global expert in tau pathology. This research demonstrated MB-204's ability to significantly reduce tau hyperphosphorylation in mice - a core aspect of Alzheimer's disease - highlighting

Marvel Biosciences Selected to Present Alzheimer's Research at the 2025 Alzheimer's Association International Conference

Mon, 14 Apr 2025 07:00:00 -0400

Marvel to File for Orphan Drug Designation with The U.S. FDA for MB-204 as a Treatment for Rett Syndrome

Mon, 17 Mar 2025 07:00:00 -0400

Calgary, Alberta--(Newsfile Corp. - March 17, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announced plans to ﬁle for Orphan Drug Designation (ODD) with the U.S. Food and Drug Administration (FDA) for its lead compound, MB-204, as a potential treatment for Rett Syndrome.

This decision follows strong preclinical data showing MB-204's sustained beneﬁts, outperforming Troﬁnetide-the only FDA-approved treatment for the disease. Marvel aims to leverage ODD beneﬁts to accelerate MB-204's clinical development and provide new hope to patients and families.

Marvel's preclinical study, conducted in collaboration with the

Marvel to File for Orphan Drug Designation with The U.S. FDA for MB-204 as a Treatment for Rett Syndrome

Mon, 17 Mar 2025 07:00:00 -0400

Marvel's preclinical study, conducted in collaboration with the

Marvel Announces First of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide

Thu, 13 Mar 2025 07:00:00 -0400

Calgary, Alberta--(Newsfile Corp. - March 13, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to share part of the final data from its preclinical Rett syndrome study conducted in collaboration with the iBraiN Institute.

The study evaluated MB-204, Marvel's lead compound (10 mg/kg oral once daily), in comparison to Trofinetide (100 mg/kg injected once daily), the only FDA and Health Canada approved treatment for Rett syndrome. Mecp2 mice were treated for approximately two weeks with either compound, and multiple endpoints were assessed while on drug

Marvel Announces First of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide

Thu, 13 Mar 2025 07:00:00 -0400

Marvel Presenting at the 2025 Bloom Burton & Co. Conference

Tue, 11 Mar 2025 07:00:00 -0400

Calgary, Alberta--(Newsfile Corp. - March 11, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today is pleased to announce it will be attending and presenting at the Bloom Burton & Co. Healthcare Investor Conference (the "Conference") taking place at the Metro Toronto Convention Centre, on May 5 and 6, 2025.

The Conference brings together U.S., Canadian and international investors who are interest in the latest developments in the Canadian healthcare sector. Marvel's CEO Rod Matheson and CSO Mark Williams, will make an in-person group presentation and also

Marvel Presenting at the 2025 Bloom Burton & Co. Conference

Tue, 11 Mar 2025 07:00:00 -0400

Marvel Biosciences Announces Notice of Allowance of Composition of Matter Patent for Its Lead Molecule MB-204 in China

Thu, 16 Jan 2025 07:00:00 -0400

Calgary, Alberta--(Newsfile Corp. - January 16, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today is pleased to announce that the Chinese patent office has issued a notice of allowance for its lead compound MB-204. This is the first allowance worldwide for this family.

"We are pleased with this allowance of claims to secure key composition of matter intellectual property protection for MB-204, and anticipate additional such notices for other countries," commented Rod Matheson, CEO of Marvel Biosciences. "MB-204 is a novel fluorinated derivative of the approved

Marvel Biosciences Announces Notice of Allowance of Composition of Matter Patent for Its Lead Molecule MB-204 in China

Thu, 16 Jan 2025 07:00:00 -0400

Marvel Biosciences Announces Private Placement for up to $2.5 Million

Tue, 07 Jan 2025 07:00:00 -0400

Calgary, Alberta--(Newsfile Corp. - January 7, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") is pleased to announce that it intends to complete a non-brokered private placement of common shares of ‎the Company (each a "Common Share") at a price of $0.15 per Common Share for gross ‎proceeds of a minimum of $1,935,000 and up to a maximum of $2,500,000 (the "Offering").‎

It is anticipated that the net proceeds from the Offering will be used to pay a deposit for phase 1 clinical trials for the Company's lead compound MB-204, general and administrative expenses and for

Marvel Biosciences Announces Private Placement for up to $2.5 Million

Tue, 07 Jan 2025 07:00:00 -0400

It is anticipated that the net proceeds from the Offering will be used to pay a deposit for phase 1 clinical trials for the Company's lead compound MB-204, general and administrative expenses and for

Marvel Biosciences Announces Promising New Data from Rett Syndrome Study and Plans to Discuss Orphan and Rare Disease Status with the FDA

Tue, 26 Nov 2024 07:00:00 -0400

Calgary, Alberta--(Newsfile Corp. - November 26, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), are pleased to share additional data from its ongoing preclinical Rett syndrome study conducted in collaboration with the iBraiN Institute. Marvel also announces plans to engage with the FDA to discuss these promising pilot results.

The study evaluated MB204, Marvel's lead compound, in comparison to Trofinetide, the only FDA and Health Canada approved treatment for Rett syndrome. Mice were treated for two weeks with either compound, and social behaviour endpoints were assessed when

Marvel Biosciences Announces Promising New Data from Rett Syndrome Study and Plans to Discuss Orphan and Rare Disease Status with the FDA

Tue, 26 Nov 2024 07:00:00 -0400

Marvel Biosciences Secures $300,000 Grant to Advance Groundbreaking Alzheimer's Research

Thu, 21 Nov 2024 07:00:00 -0400

Calgary, Alberta--(Newsfile Corp. - November 21, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today is pleased to announce it has been awarded the Alberta Innovates AICE Validates grant, securing $300,000 in funding to support the preclinical validation of MB204 as a treatment for Alzheimer's disease. This funding represents a significant step forward for Marvel, providing the resources and recognition needed to advance toward clinical trials.

Alzheimer's disease is a devastating and widespread form of dementia, affecting 1 in 10 Canadians over 65 and nearly 50,000 Albertans.

Marvel Biosciences Secures $300,000 Grant to Advance Groundbreaking Alzheimer's Research

Thu, 21 Nov 2024 07:00:00 -0400

Alzheimer's disease is a devastating and widespread form of dementia, affecting 1 in 10 Canadians over 65 and nearly 50,000 Albertans.

Marvel Biosciences Announces MB204 Outperforms Approved Drug Trofinetide in a Preclinical Model of Rett Syndrome

Thu, 07 Nov 2024 07:00:00 -0400

Calgary, Alberta--(Newsfile Corp. - November 7, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today reported promising interim results from its study on MB204, as a potential new treatment for Rett syndrome. The study, conducted by experts at the iBraiN Institute in Tours (France), demonstrated that chronic oral dosing of MB204 restored social interaction behaviors to near-normal levels in a preclinical model of Rett syndrome. These notable improvements in cognitive function could signify a pivotal shift in therapy.

The study, led by Dr. Julie Le Merrer and

Marvel Biosciences Announces MB204 Outperforms Approved Drug Trofinetide in a Preclinical Model of Rett Syndrome

Thu, 07 Nov 2024 07:00:00 -0400

The study, led by Dr. Julie Le Merrer and

Marvel Biosciences Shares Positive Results of MB204 in the Oprm1 Model of Autism

Thu, 10 Oct 2024 09:00:00 -0400

Calgary, Alberta--(Newsfile Corp. - October 10, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today shared promising results from a recent study on MB204. The research was conducted by Drs. Julie Le Merrer and Jerome Becker of the iBraiN Institute in Tours, France, to investigate the impact of MB204 in the Oprm1 mouse model of autism (widely used to study social behavior deficits). Marvel is pleased to report that just one hour after administering a single oral dose of MB204, the drug successfully reversed the social